Ann: Results of Phase 2 Clinical Trial, page-106

The observations are correct.
With TIS we were wIth "a great product unable to enter in the EU due to a badly run small sized trial" to now "a failure not divergent from a placebo."
There is something really wrong here.
Or there is a plan to transfer this technology out from FTT for zero value, or we have been in the TIS past and FTT now played out as babies.

Simply does not make any sense that a good product transforms itself to this.

What was the outcome and sense of the EU time lost Trial? We should have Dr. Steve Mercer coming to the table and explain truly how the reality stands for this technology.
Logically, it hurts a lot to see this. We all had big expectations on this trial. The funds supported and recovered this company with the previous capital raising, Chris B. was recruIted by the Sidney mutual fund, the BOD investigations were leading to a good product run by a bad previous management. Chris B. stated this in the past.

OK now we are all in deep shit and all have lost tons of money. The market cap is no-existent as there is no value. Is this an overreaction or an error before the actual full reading and disclosure of data? We should see all datavin detsils before considering this story a terrible outvome.

What is the real value of all this TIS/FTT story?